Pharmaids Pharma

{
  "main_header": {
    "sid": 799751,
    "name": "Pharmaids Pharma",
    "stock_name": "Pharmaids Pharma",
    "full_name": "Pharmaids Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/pharmaids-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "47.39",
    "chg": 0.09,
    "chgp": "0.19%",
    "dir": 1,
    "prev_price": "47.30",
    "mcapval": "167.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524572,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE117D01018",
    "curr_date": "Jan 19",
    "curr_time": "",
    "bse_nse_vol": "1.04 k",
    "exc_status": "Active",
    "traded_date": "Jan 19, 2026",
    "traded_date_str": "2026 01 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/pharmaids-pharma-799751-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Pharmaids Pharmaceuticals Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-pharmaids-pharmaceuticals-ltd-fallingrising-3783763",
        "imagepath": "",
        "date": "2026-01-07 02:39:49",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Relative Performance</strong></p>\n<p>Pharmaids Pharmaceuticals Ltd’s share price has shown mixed trends over the short term but remains under pressure over longer periods. While the stock recorded a modest gain of 0.73% over the past week, this outperformance is marginal compared to the Sensex’s 0.46% rise. However, the stock’s one-month return of -7.05% significantly underperforms the Sensex’s decline of just 0.76%, signalling growing investor caution. Year-to-date, the stock is down 1.51%, lagging the benchmark’s 0.18% fall.</p>\n<p>More notably, the stock has suffered a steep 40.21% decline over the past year, contrasting sharply with the Sensex’s 9.10% gain during the same period. This stark divergence highlights the challenges Pharmaids Pharmaceuticals faces in ..."
      },
      {
        "title": "Pharmaids Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pharmaids-pharmaceuticals-ltd-is-rated-strong-sell-3781608",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/PharmaidsPharma_mojoScore_3781608.png",
        "date": "2026-01-05 10:11:38",
        "description": "Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed here represent the company’s current position as of 05 January 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance."
      },
      {
        "title": "Pharmaids Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pharmaids-pharmaceuticals-ltd-is-rated-strong-sell-3769248",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/PharmaidsPharma_mojoScore_3769248.png",
        "date": "2025-12-25 12:57:37",
        "description": "Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Pharmaids Pharma Sees Revision in Market Evaluation Amidst Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pharmaids-pharma-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-outlook-3746457",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/PharmaidsPharma_mojoScore_3746457.png",
        "date": "2025-12-04 11:08:19",
        "description": "Pharmaids Pharma has undergone a revision in its market evaluation, reflecting a more cautious analytical perspective driven by recent financial and technical developments. The shift highlights concerns over the company’s operational performance and market positioning within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Why is Pharmaids Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-pharmaids-pharma-fallingrising-3708698",
        "imagepath": "",
        "date": "2025-11-17 23:01:35",
        "description": "As of 17-Nov, Pharmaids Pharmaceuticals Ltd is experiencing a price increase, currently at Rs 47.82, which reflects a rise of Rs 3.41 or 7.68%. Today's price summary indicates that the stock opened with a gain of 4.48% and reached an intraday high of Rs 48, marking an 8.08% increase. However, despite this positive movement, the stock has shown a decline of 1.24% over the past week and a significant drop of 32.15% year-to-date. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 66.97% against the 5-day average, which may indicate waning interest despite today's gains.\n\nBroader market context shows that while Pharmaids Pharmaceuticals has outperformed its sector by 7.4% today, it has underperformed the Sensex over the past week and month, which have seen gains of 1.69% and 1.19%, respectively. The stock's long-term performance remains strong, with a 3-ye..."
      },
      {
        "title": "Why is Pharmaids Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-pharmaids-pharma-fallingrising-3702580",
        "imagepath": "",
        "date": "2025-11-14 23:01:57",
        "description": "As of 14-Nov, Pharmaids Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 44.13, which reflects a decrease of Rs 1.68 or 3.67%. The stock has underperformed significantly today, with a performance that is 4.04% lower than its sector. It has also touched an intraday low of Rs 43.9, indicating a drop of 4.17%. The stock is trading below all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), and there has been a notable decrease in investor participation, with delivery volume falling by 29.48% compared to the 5-day average. Furthermore, the stock is close to its 52-week low, being only 4.83% away from Rs 42. The year-to-date return is down by 37.39%, and the one-year return shows a decline of 41.90%, highlighting a significant downturn in performance.\n\nIn the broader market context, the Sensex has shown a positive return of 1.62% over the past week, contrasting s..."
      },
      {
        "title": "How has been the historical performance of Pharmaids Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-pharmaids-pharma-3694747",
        "imagepath": "",
        "date": "2025-11-12 23:53:35",
        "description": "Answer:\nThe historical performance of Pharmaids Pharma shows a gradual increase in net sales, reaching 19.45 Cr in March 2025, up from 15.11 Cr in March 2024 and starting from 0.00 Cr in March 2023. However, the company has consistently reported negative operating profits, with an operating profit of -12.66 Cr in March 2025, slightly worse than -12.33 Cr in March 2024 and -9.88 Cr in March 2023. The total expenditure has risen to 32.21 Cr in March 2025 from 28.32 Cr in March 2024, contributing to a profit before tax of -17.28 Cr in March 2025, compared to -15.62 Cr in March 2024 and -9.91 Cr in March 2023. The profit after tax also reflects this trend, with losses of -13.51 Cr in March 2025, -11.84 Cr in March 2024, and -7.56 Cr in March 2023. The company's total assets increased to 109.35 Cr in March 2025 from 84.67 Cr in March 2024, while total liabilities also rose to 109.35 Cr from 84.67 Cr, indicating ..."
      },
      {
        "title": "Are Pharmaids Pharma latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-pharmaids-pharma-latest-results-good-or-bad-3693212",
        "imagepath": "",
        "date": "2025-11-12 19:31:25",
        "description": "Pharmaids Pharmaceuticals has reported its financial results for Q2 FY26, revealing a complex situation characterized by significant revenue growth alongside persistent operational challenges. The company achieved net sales of ₹8.61 crores, marking a year-on-year growth of 64.31% and a quarter-on-quarter increase of 29.28%. This represents the highest quarterly revenue in the company's history. However, despite this top-line expansion, Pharmaids continues to face substantial net losses, reporting a consolidated net loss of ₹2.48 crores for the quarter, which reflects a 28.50% deterioration year-on-year.\n\nThe operating margin remains deeply negative at -61.67%, indicating ongoing struggles with cost management and profitability. The company's PAT margin also stands at a negative -29.38%, underscoring the challenges in converting revenue into profit. Notably, employee costs have risen significantly, consuming..."
      },
      {
        "title": "Pharmaids Pharmaceuticals Q2 FY26: Mounting Losses and Deteriorating Margins Signal Deepening Crisis",
        "link": "https://www.marketsmojo.com/news/result-analysis/pharmaids-pharmaceuticals-q2-fy26-mounting-losses-and-deteriorating-margins-signal-deepening-crisis-3692709",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PharmaidsPharma_quaterlyResult_3692709.png",
        "date": "2025-11-12 09:46:45",
        "description": "Pharmaids Pharmaceuticals Ltd., a Hyderabad-based micro-cap pharmaceutical company, reported a consolidated net loss of ₹2.48 crores in Q2 FY26, marking a deterioration of 28.50% year-on-year from the ₹1.93 crore loss in Q2 FY25. The company's stock has plummeted 44.43% over the past year, currently trading at ₹46.29 with a market capitalisation of ₹162.00 crores, reflecting investor exodus from this loss-making enterprise."
      }
    ],
    "total": 91,
    "sid": "799751",
    "stock_news_url": "https://www.marketsmojo.com/news/pharmaids-pharmaceuticals-799751"
  },
  "announcements": [
    {
      "caption": "Re-Lodgement Of Requests For Transfer Of Physical Shares",
      "datetime": "16-Jan-2026",
      "details": "Report on shares re-lodged for transfer cum Demat of Physical shares.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "12-Jan-2026",
      "details": "Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "05-Jan-2026",
      "details": "Intimation regarding completion of term of Independent Director of Mr. Mopperthy Sudheer",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Pharmaids Pharmaceuticals Ltd falling/rising?

2026-01-07 02:39:49

Recent Price Movement and Relative Performance

Pharmaids Pharmaceuticals Ltd’s share price has shown mixed trends over the short term but remains under pressure over longer periods. While the stock recorded a modest gain of 0.73% over the past week, this outperformance is marginal compared to the Sensex’s 0.46% rise. However, the stock’s one-month return of -7.05% significantly underperforms the Sensex’s decline of just 0.76%, signalling growing investor caution. Year-to-date, the stock is down 1.51%, lagging the benchmark’s 0.18% fall.

More notably, the stock has suffered a steep 40.21% decline over the past year, contrasting sharply with the Sensex’s 9.10% gain during the same period. This stark divergence highlights the challenges Pharmaids Pharmaceuticals faces in ...

Read full news article

Pharmaids Pharmaceuticals Ltd is Rated Strong Sell

2026-01-05 10:11:38

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed here represent the company’s current position as of 05 January 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance.

Read full news article

Pharmaids Pharmaceuticals Ltd is Rated Strong Sell

2025-12-25 12:57:37

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Pharmaids Pharma Sees Revision in Market Evaluation Amidst Challenging Fundamentals

2025-12-04 11:08:19

Pharmaids Pharma has undergone a revision in its market evaluation, reflecting a more cautious analytical perspective driven by recent financial and technical developments. The shift highlights concerns over the company’s operational performance and market positioning within the Pharmaceuticals & Biotechnology sector.

Read full news article

Why is Pharmaids Pharma falling/rising?

2025-11-17 23:01:35

As of 17-Nov, Pharmaids Pharmaceuticals Ltd is experiencing a price increase, currently at Rs 47.82, which reflects a rise of Rs 3.41 or 7.68%. Today's price summary indicates that the stock opened with a gain of 4.48% and reached an intraday high of Rs 48, marking an 8.08% increase. However, despite this positive movement, the stock has shown a decline of 1.24% over the past week and a significant drop of 32.15% year-to-date. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 66.97% against the 5-day average, which may indicate waning interest despite today's gains. Broader market context shows that while Pharmaids Pharmaceuticals has outperformed its sector by 7.4% today, it has underperformed the Sensex over the past week and month, which have seen gains of 1.69% and 1.19%, respectively. The stock's long-term performance remains strong, with a 3-ye...

Read full news article

Why is Pharmaids Pharma falling/rising?

2025-11-14 23:01:57

As of 14-Nov, Pharmaids Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 44.13, which reflects a decrease of Rs 1.68 or 3.67%. The stock has underperformed significantly today, with a performance that is 4.04% lower than its sector. It has also touched an intraday low of Rs 43.9, indicating a drop of 4.17%. The stock is trading below all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), and there has been a notable decrease in investor participation, with delivery volume falling by 29.48% compared to the 5-day average. Furthermore, the stock is close to its 52-week low, being only 4.83% away from Rs 42. The year-to-date return is down by 37.39%, and the one-year return shows a decline of 41.90%, highlighting a significant downturn in performance. In the broader market context, the Sensex has shown a positive return of 1.62% over the past week, contrasting s...

Read full news article

How has been the historical performance of Pharmaids Pharma?

2025-11-12 23:53:35

Answer: The historical performance of Pharmaids Pharma shows a gradual increase in net sales, reaching 19.45 Cr in March 2025, up from 15.11 Cr in March 2024 and starting from 0.00 Cr in March 2023. However, the company has consistently reported negative operating profits, with an operating profit of -12.66 Cr in March 2025, slightly worse than -12.33 Cr in March 2024 and -9.88 Cr in March 2023. The total expenditure has risen to 32.21 Cr in March 2025 from 28.32 Cr in March 2024, contributing to a profit before tax of -17.28 Cr in March 2025, compared to -15.62 Cr in March 2024 and -9.91 Cr in March 2023. The profit after tax also reflects this trend, with losses of -13.51 Cr in March 2025, -11.84 Cr in March 2024, and -7.56 Cr in March 2023. The company's total assets increased to 109.35 Cr in March 2025 from 84.67 Cr in March 2024, while total liabilities also rose to 109.35 Cr from 84.67 Cr, indicating ...

Read full news article

Are Pharmaids Pharma latest results good or bad?

2025-11-12 19:31:25

Pharmaids Pharmaceuticals has reported its financial results for Q2 FY26, revealing a complex situation characterized by significant revenue growth alongside persistent operational challenges. The company achieved net sales of ₹8.61 crores, marking a year-on-year growth of 64.31% and a quarter-on-quarter increase of 29.28%. This represents the highest quarterly revenue in the company's history. However, despite this top-line expansion, Pharmaids continues to face substantial net losses, reporting a consolidated net loss of ₹2.48 crores for the quarter, which reflects a 28.50% deterioration year-on-year. The operating margin remains deeply negative at -61.67%, indicating ongoing struggles with cost management and profitability. The company's PAT margin also stands at a negative -29.38%, underscoring the challenges in converting revenue into profit. Notably, employee costs have risen significantly, consuming...

Read full news article

Pharmaids Pharmaceuticals Q2 FY26: Mounting Losses and Deteriorating Margins Signal Deepening Crisis

2025-11-12 09:46:45

Pharmaids Pharmaceuticals Ltd., a Hyderabad-based micro-cap pharmaceutical company, reported a consolidated net loss of ₹2.48 crores in Q2 FY26, marking a deterioration of 28.50% year-on-year from the ₹1.93 crore loss in Q2 FY25. The company's stock has plummeted 44.43% over the past year, currently trading at ₹46.29 with a market capitalisation of ₹162.00 crores, reflecting investor exodus from this loss-making enterprise.

Read full news article

View All News